{"abstract":"This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Kite Pharma, Inc. (\"Kite\") located in Santa Monica, CA to practice the inventions embodied in the following patent applications:","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2016/08/17/2016-19549.html","cfr_references":[],"citation":"81 FR 54817","comment_url":null,"comments_close_on":"2016-09-01","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Cancer Institute on or before September 1, 2016 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2016-19549","effective_on":null,"end_page":54817,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2016/08/17/2016-19549.xml","html_url":"https://www.federalregister.gov/documents/2016/08/17/2016-19549/prospective-grant-of-exclusive-patent-license-development-of-t-cell-receptors-tcrs-targeting-the","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2016-19549?publication_date=2016-08-17","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2016-08-17/2016-19549/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":542,"last_updated":"2026-06-27 00:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2016-08-17/pdf/2016-19549.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2016-19549.pdf?1471351537","publication_date":"2016-08-17","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2016/08/17/2016-19549.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T00:32:35Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":54817,"subtype":null,"title":"Prospective Grant of Exclusive Patent License: Development of T Cell Receptors (TCRs) Targeting the KRAS G12D Mutation for the Treatment of Cancer","toc_doc":"Development of T Cell Receptors Targeting the KRAS G12D Mutation for the Treatment of Cancer","toc_subject":"Prospective Grant of Exclusive Patent License:","topics":[],"type":"Notice","volume":81}